Indivior's Commitment to Opioid Use Disorder Recovery
Indivior PLC, focusing on substance use disorders, is advocating for better access to medications for opioid use disorder (OUD) during Substance Abuse Prevention Month. Their recent studies provide strong evidence supporting the efficacy and safety of SUBLOCADE, a once-monthly extended-release injection of buprenorphine, designed to treat moderate to severe OUD.
Key Findings from Recent Publications
Research has highlighted the importance of access to long-acting injectable treatments like SUBLOCADE, noting that overcoming barriers is essential for better patient outcomes. Significant findings include:
- The findings from a post hoc analysis of a clinical trial published in Harm Reduction Journal demonstrated that the 300 mg maintenance dose of SUBLOCADE resulted in a notable increase in abstinence among patients who inject opioids compared to those receiving a 100 mg dose.
- The CoLAB Study indicated that participants maintained on SUBLOCADE for 96 weeks experienced continuous improvements in abstinence and overall quality of life.
- A qualitative survey published in American Health & Drug Benefits discovered that while telemedicine emerged as a vital solution during the pandemic, barriers to accessing medications for OUD still persist today.
- A literature review published in Corrections Today highlighted the disparities in access to medications for OUD between the general population and incarcerated individuals, revealing significant stigma that impedes treatment options for those in correctional settings.
Upcoming Presentations and Studies
Indivior is set to present at several prominent conferences, focusing on the ongoing challenges and solutions in treating OUD:
- During the 2024 American Association of Psychiatric Pharmacists conference, Indivior will discuss opioid treatment programs and healthcare costs related to buprenorphine extended-release treatment.
- At the 2024 American Telemedicine Association Nexus, the impact of telemedicine on patient retention during the pandemic will be a key discussion point.
- The College on Problems of Drug Dependence will host presentations centered on the management of OUD post-emergency department visits and the effectiveness of buprenorphine treatment induction strategies.
- The U.S. Public Health Service Symposium will feature insights into the unique treatment characteristics necessary for managing OUD in American Indian and Alaska Native populations.
- In August, a virtual conference will address healthcare utilization for OUD management within various treatment programs.
Dr. Heidbreder's Insights
Dr. Christian Heidbreder, Chief Scientific Officer at Indivior, emphasizes the necessity of access to effective medications like SUBLOCADE, stating that these treatments significantly enhance adherence and recovery outcomes for individuals battling OUD. With millions of people suffering from opioid dependence, Indivior remains committed to eradicating barriers and fostering understanding around these chronic conditions.
Understanding SUBLOCADE
SUBLOCADE is not just a medication; it represents a comprehensive approach to OUD treatment. To use SUBLOCADE effectively, patients must first begin with a buprenorphine-containing product, ensuring they are medically stable before transitioning to this long-term solution. It plays a crucial role in a treatment plan that complements counseling and psychosocial support.
Indications and Safety Information
While SUBLOCADE offers promising benefits, it is important to note its risks—primarily associated with intravenous administration, which can lead to severe complications. The medication is restricted under the SUBLOCADE REMS Program, ensuring that it is administered safely and effectively.
About Opioid Use Disorder
OUD is a serious, chronic condition that can severely impact individuals’ lives. Given the alarming statistics indicating only a small fraction of those affected are receiving treatment, it is critical to enhance awareness and access to effective treatments like those offered by Indivior.
Conclusion
In conclusion, Indivior stands at the forefront of combating OUD through evidence-based practices and innovative treatment options. By enhancing access to SUBLOCADE and focusing on patient outcomes, the company aims to shift the perception of OUD from a stigma-laden condition to a manageable chronic disease that deserves comprehensive care and attention.
Frequently Asked Questions
What is SUBLOCADE?
SUBLOCADE is a once-monthly extended-release injection of buprenorphine designed to treat moderate to severe opioid use disorder.
How does SUBLOCADE work?
SUBLOCADE works by reducing withdrawal symptoms and cravings associated with opioid use disorder, helping individuals achieve long-term recovery.
What are the benefits of using SUBLOCADE?
Using SUBLOCADE improves patient adherence and helps increase rates of abstinence from opioids when combined with counseling and support.
What safety measures are involved with SUBLOCADE?
SUBLOCADE is part of a restricted program due to risks associated with intravenous use. It must be administered by certified healthcare professionals.
Why is access to medications for OUD important?
Access to effective treatments like SUBLOCADE is critical for reducing barriers to recovery and enhancing outcomes for individuals struggling with opioid use disorder.
